1-4 of 4
Helen Brown
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Identifying PTPRJ As a Novel Mediator of CEBPA -Mutated AML

Alexandra Lubin, Catherine Hockings, Yvette Hoade, Lucy Copper, Phoebe Dace, Catherine Zhu, Helen Brown, Ellen Nuttall Musson, Katie-Jo Miller, Elspeth Payne
Journal: Blood
Blood (2023) 142 (Supplement 1): 2755.
https://doi.org/10.1182/blood-2023-177577
Published: 2023
Journal Articles

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study

Clinical Trials & Observations Brief Report
Farheen Mir, Sally F. Barrington, Helen Brown, Tina Nielsen, Deniz Sahin, Michel Meignan, Judith Trotman
Journal: Blood
Blood (2020) 135 (15): 1214–1218.
https://doi.org/10.1182/blood.2019001091
Published: 2020
Includes: Supplemental data
Journal Articles

Baseline Suvmax Did Not Predict Histological Transformation from Follicular Lymphoma to Aggressive Lymphoma in the Phase III GALLIUM Study

Farheen Mir, MBBS, Sally F Barrington, Michel Meignan, Helen Brown, Tina Nielsen, Deniz Sahin, Judith Trotman
Journal: Blood
Blood (2018) 132 (Supplement 1): 4160.
https://doi.org/10.1182/blood-2018-99-116686
Published: 2018
Journal Articles

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Christiane Pott, Eva Hoster, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, Michael Kneba, Jiri Mayer, MD, Christopher Pocock, MD PhD, Andrea Knapp, Nathalie Danesi, Tina Nielsen, Helen Brown, Kirsten Mundt, Robert Marcus, Wolfgang Hiddemann
Journal: Blood
Blood (2018) 132 (Supplement 1): 396.
https://doi.org/10.1182/blood-2018-99-115930
Published: 2018